Psychopharmacology

Papers
(The H4-Index of Psychopharmacology is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Cannabidiol: pharmacology and therapeutic targets160
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials97
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants85
A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats63
Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada60
Chronic mild stress paradigm as a rat model of depression: facts, artifacts, and future perspectives58
Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review56
Serotonin toxicity of serotonergic psychedelics52
7,8-Dihydroxyflavone improves cognitive functions in ICV-STZ rat model of sporadic Alzheimer’s disease by reversing oxidative stress, mitochondrial dysfunction, and insulin resistance51
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world49
(R)-Ketamine attenuates LPS-induced endotoxin-derived delirium through inhibition of neuroinflammation45
Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research44
The acute effects of classic psychedelics on memory in humans39
Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review39
The zebrafish (Danio rerio) anxiety test battery: comparison of behavioral responses in the novel tank diving and light–dark tasks following exposure to anxiogenic and anxiolytic compounds38
Expectancy in placebo-controlled trials of psychedelics: if so, so what?37
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia36
A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions36
Treatment of opioid overdose: current approaches and recent advances36
Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults36
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review36
A buprenorphine-validated rat model of opioid use disorder optimized to study sex differences in vulnerability to relapse35
Pharmacokinetic and pharmacodynamic properties of aerosolized (“vaped”) THC in adolescent male and female rats35
Geniposide ameliorates chronic unpredictable mild stress induced depression-like behavior through inhibition of ceramide-PP2A signaling via the PI3K/Akt/GSK3β axis33
Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine32
Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants32
Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study31
Animal models of chemotherapy-induced cognitive decline in preclinical drug development31
Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review31
RETRACTED ARTICLE: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy30
Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations30
Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty2130
0.042868852615356